Digital Transformation in the Life Sciences Accelerates, Set to Reshape Industry Across Next Decade

Published on : Published by : Steven Surdez

Like many other industry sectors, the bioscience space has been slow to embrace the digital future. Investing in and building out an integrated, enterprise-wide digital platform always played second fiddle to funding R&D, hiring, manufacturing and the commercial function. A Deloitte “Perspectives” piece perhaps framed the current state of digital transformation in the life sciences best, suggesting that organizations need to move “…from merely doing digital to being digital” or risk irrelevancy. 

Kevin Hannigan Appointed CEO at Automated Control Concepts

Published on : Published by : BioBuzz Media

Automated Control Concepts (ACC) is proud to announce that Kevin Hannigan has been appointed CEO. Kevin’s previous leadership as President of ACC has been instrumental in helping ACC achieve our recent level of remarkable success, culminating in the investment from our new partners, Sverica Capital Management. His vision for our growth is exciting and frankly inspirational.

Lab Owl® a Key Contributor to Advanced Regenerative Manufacturing Institute’s Mission

Published on : Published by : Steven Surdez

consortium in 2019. Since that time, the Lab Owl product has been integrated into ARMI’s Tissue Foundry manufacturing process, and the Lab Owl team has made important contributions to several working groups tasked with solving some of the challenges facing tissue engineering and regenerative medicine manufacturing. These working groups include establishing ARMI’s Workforce Characteristics Charter; the Tissue Maturation and Bioreactor Charter; and the Cell Culture and Harvest Charter.

5 Questions with Kurt Elam, Senior Director, Sales & Marketing for LabOwl

Published on : Published by : Andy Eckert

Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.